A human model of Buruli ulcer: The case for controlled human infection and considerations for selecting a Mycobacterium ulcerans challenge strain.

Humans Mycobacterium ulcerans Buruli Ulcer / prevention & control Host-Pathogen Interactions Knowledge Neglected Diseases

Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
Jun 2023
Historique:
medline: 3 7 2023
pubmed: 29 6 2023
entrez: 29 6 2023
Statut: epublish

Résumé

Critical knowledge gaps regarding infection with Mycobacterium ulcerans, the cause of Buruli ulcer (BU), have impeded development of new therapeutic approaches and vaccines for prevention of this neglected tropical disease. Here, we review the current understanding of host-pathogen interactions and correlates of immune protection to explore the case for establishing a controlled human infection model of M. ulcerans infection. We also summarise the overarching safety considerations and present a rationale for selecting a suitable challenge strain.

Identifiants

DOI: 10.1371/journal.pntd.0011394 PMID: 37384606 PMC: PMC10309606
pubmed: 37384606
doi: 10.1371/journal.pntd.0011394
pii: PNTD-D-23-00359
pmc: PMC10309606
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0011394

Informations de copyright

Copyright: © 2023 Muhi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2016 Nov 28;11(11):e0167059
pubmed: 27893778
Biol Cell. 2018 Nov;110(11):237-248
pubmed: 30055020
Intern Med J. 2017 Sep;47(9):1011-1019
pubmed: 28585259
J Infect Dis. 2009 Dec 1;200(11):1675-84
pubmed: 19863437
Clin Infect Dis. 2014 Nov 1;59(9):1256-64
pubmed: 25048846
PLoS Negl Trop Dis. 2014 Apr 10;8(4):e2770
pubmed: 24722416
Infect Immun. 2007 Feb;75(2):977-87
pubmed: 17145944
mSphere. 2019 Feb 13;4(1):
pubmed: 30760615
PLoS Negl Trop Dis. 2010 Dec 14;4(12):e911
pubmed: 21179505
PLoS Negl Trop Dis. 2014 Jan 30;8(1):e2668
pubmed: 24498452
Am J Trop Med Hyg. 1995 Mar;52(3):219-24
pubmed: 7694962
PLoS Negl Trop Dis. 2019 Feb 19;13(2):e0007178
pubmed: 30779807
BMC Infect Dis. 2013 Sep 05;13:416
pubmed: 24007371
PLoS Negl Trop Dis. 2015 Dec 02;9(12):e0004253
pubmed: 26630648
J Pathol Bacteriol. 1948 Jan;60(1):93-122
pubmed: 18876541
Sci Adv. 2020 Feb 26;6(9):eaax7781
pubmed: 32133396
PLoS Negl Trop Dis. 2014 Jan 02;8(1):e2612
pubmed: 24392172
Infect Genet Evol. 2012 Apr;12(3):522-9
pubmed: 22306192
Front Immunol. 2022 Nov 08;13:1023558
pubmed: 36426350
Emerg Infect Dis. 2017 May;23(5):837-840
pubmed: 28418294
Vaccine. 2012 Feb 1;30(6):1038-49
pubmed: 22189700
Infect Immun. 2005 Oct;73(10):6299-310
pubmed: 16177301
J Exp Med. 2016 Dec 12;213(13):2885-2896
pubmed: 27821549
Lancet. 2020 Apr 18;395(10232):1259-1267
pubmed: 32171422
Lancet. 2017 Jan 21;389(10066):312-325
pubmed: 27639954
J Infect Dis. 2012 Apr 1;205(7):1035-42
pubmed: 22396610
Med J Aust. 2014 Mar 17;200(5):267-70
pubmed: 24641151
Antimicrob Agents Chemother. 2020 May 21;64(6):
pubmed: 32205344
PLoS Negl Trop Dis. 2016 Feb 10;10(2):e0004450
pubmed: 26863011
PLoS Negl Trop Dis. 2018 Aug 13;12(8):e0006724
pubmed: 30102695
Antimicrob Agents Chemother. 2007 Oct;51(10):3737-9
pubmed: 17664316
Antimicrob Agents Chemother. 2020 Aug 20;64(9):
pubmed: 32571813
Emerg Infect Dis. 2000 Mar-Apr;6(2):158-64
pubmed: 10756149
Int J Microbiol. 2016;2016:8304524
pubmed: 28070190
Infect Immun. 2003 Feb;71(2):774-83
pubmed: 12540557
Infect Immun. 2004 Feb;72(2):958-65
pubmed: 14742541
Cell Host Microbe. 2019 Apr 10;25(4):484-498
pubmed: 30974083
BMC Evol Biol. 2007 Sep 27;7:177
pubmed: 17900363
Cell Microbiol. 2005 Sep;7(9):1295-304
pubmed: 16098217
Materials (Basel). 2022 Jun 29;15(13):
pubmed: 35806714
PLoS Negl Trop Dis. 2019 Aug 26;13(8):e0007689
pubmed: 31449522
Cell Death Dis. 2018 Mar 14;9(3):397
pubmed: 29540678
Infect Immun. 2001 Mar;69(3):1704-7
pubmed: 11179346
Front Med (Lausanne). 2018 Oct 29;5:297
pubmed: 30420951
Chembiochem. 2007 Nov 23;8(17):2043-7
pubmed: 17907121
Epidemiol Infect. 2018 Oct 08;147:e19
pubmed: 30293536
PLoS Negl Trop Dis. 2012 Jan;6(1):e1460
pubmed: 22253937
PLoS Negl Trop Dis. 2015 Mar 05;9(3):e0003549
pubmed: 25742173
Infect Immun. 2002 Oct;70(10):5562-7
pubmed: 12228283
Clin Vaccine Immunol. 2009 Jan;16(1):61-5
pubmed: 19005025
Emerg Infect Dis. 2007 Nov;13(11):1653-60
pubmed: 18217547
Vaccine. 2021 Dec 8;39(50):7238-7252
pubmed: 34119347
Plast Surg Int. 2012;2012:752749
pubmed: 22666574
FEMS Microbiol Lett. 1999 Dec 1;181(1):153-7
pubmed: 10564801
PLoS Negl Trop Dis. 2017 Aug 18;11(8):e0005800
pubmed: 28821017
ACS Chem Biol. 2017 May 19;12(5):1297-1307
pubmed: 28294596
Clin Vaccine Immunol. 2006 Dec;13(12):1314-21
pubmed: 17021247
Adv Parasitol. 2018;100:39-126
pubmed: 29753342
PLoS Negl Trop Dis. 2013;7(3):e2143
pubmed: 23556027
PLoS Negl Trop Dis. 2013 Oct 03;7(10):e2463
pubmed: 24098820
Clin Infect Dis. 2003 Apr 15;36(8):1076-7
pubmed: 12684923
Med J Aust. 2018 Apr 16;208(7):290-291
pubmed: 29642809
Clin Infect Dis. 2016 Feb 1;62(3):342-350
pubmed: 26486698
Med J Aust. 2018 Apr 16;208(7):287-289
pubmed: 29642808
Clin Exp Immunol. 2007 Dec;150(3):451-9
pubmed: 17900302
Med J Aust. 2012 Mar 19;196(5):341-4
pubmed: 22432674
Aust N Z J Surg. 1972 May;41(4):317-9
pubmed: 4554345
Clin Exp Immunol. 2006 Mar;143(3):445-51
pubmed: 16487243
PLoS Negl Trop Dis. 2010 Nov 02;4(11):e872
pubmed: 21072233
J Med Case Rep. 2015 May 01;9:98
pubmed: 25927351
Genome Res. 2007 Feb;17(2):192-200
pubmed: 17210928
PLoS Pathog. 2014 Apr 03;10(4):e1004061
pubmed: 24699819
Clin Diagn Lab Immunol. 2005 Jan;12(1):125-9
pubmed: 15642996
Clin Microbiol Rev. 2022 Sep 21;35(3):e0000821
pubmed: 35862754
PLoS Negl Trop Dis. 2012;6(9):e1767
pubmed: 23029568
J Paediatr Child Health. 2020 Apr;56(4):636-641
pubmed: 31821679
J Exp Med. 2007 Jun 11;204(6):1395-403
pubmed: 17517970
ANZ J Surg. 2019 Jun;89(6):653-658
pubmed: 30239097
Emerg Infect Dis. 2018 Jan;24(1):
pubmed: 28980523
Infect Immun. 2020 Feb 20;88(3):
pubmed: 31818964
PLoS Negl Trop Dis. 2017 Apr 14;11(4):e0005553
pubmed: 28410412
Virulence. 2017 Nov 17;8(8):1918-1926
pubmed: 28873327
Ann Soc Belg Med Trop (1920). 1962 Aug 31;42:585-90
pubmed: 14021473
J Leukoc Biol. 2006 Jun;79(6):1150-6
pubmed: 16531561
Public Health Ethics. 2016 Apr;9(1):92-103
pubmed: 29731811
PLoS Negl Trop Dis. 2018 Mar 19;12(3):e0006323
pubmed: 29554096
Nat Med. 2020 Mar;26(3):326-332
pubmed: 32066978
PLoS Negl Trop Dis. 2010 Aug 10;4(8):e791
pubmed: 20706592
J Immunol. 1999 Oct 1;163(7):3928-35
pubmed: 10490994
Clin Microbiol Infect. 2007 Oct;13(10):1033-5
pubmed: 17697005
J Immunol. 2010 Jan 15;184(2):947-55
pubmed: 20008288

Auteurs

Stephen Muhi (S)

Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
ORCID: 0000-0003-3161-8199

Joshua Osowicki (J)

Tropical Diseases Research Group, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.
Infectious Diseases Unit, Department of General Medicine, Royal Children's Hospital Melbourne, Victoria, Australia.
Department of Paediatrics, University of Melbourne, Victoria, Australia.

Daniel O'Brien (D)

Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Barwon Health, Geelong, Victoria, Australia.

Paul D R Johnson (PDR)

Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
Austin Health, Heidelberg, Victoria, Australia.

Sacha Pidot (S)

Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.

Marcel Doerflinger (M)

Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

Julia L Marshall (JL)

Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.

Marc Pellegrini (M)

Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

James McCarthy (J)

Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Victoria, Australia.

Timothy P Stinear (TP)

Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A human model of Buruli ulcer: The case for...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobactéries non tuberculeuses › Mycobacterium ulcerans › A human model of Buruli ulcer: The case for...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Ulcère cutané › Ulcère de Buruli › A human model of Buruli ulcer: The case for...
questionsmedicales.fr › Phénomènes biologiques › Interactions hôte-microbes › Interactions hôte-pathogène › A human model of Buruli ulcer: The case for...
questionsmedicales.fr › Sciences humaines › Savoir › A human model of Buruli ulcer: The case for...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladies négligées › A human model of Buruli ulcer: The case for...